Conference Proceedings
NOVEL COMBINATION IMMUNOTHERAPY FOR BOOSTING AND PRIMING IMMUNE RESPONSES IN PANCREATIC CANCER: STRONG ANTI-TUMOUR EFFECTS WITH INTERLEUKIN-15 AND CD40 AGONIST TREATMENT
Jonas Van Audenaerde, Elly Marcq, Bianca von Scheidt, Ashleigh Davey, Amanda Oliver, Jorrit De Waele, Delphine Quatannens, Jinthe Van Loenhout, Patrick Pauwels, Geert Roeyen, Filip Lardon, Clare Slaney, Marc Peeters, Michael Kershaw, Phillip Darcy, Evelien Smits
Journal for ImmunoTherapy of Cancer | BMJ PUBLISHING GROUP | Published : 2020
Abstract
BackgroundWith the poorest 5-year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. In this era of combination immunotherapies, we sought to explore the potential of combining both priming and activation of the immune system. To achieve this, we combined a CD40 agonist with interleukin-15 and tested its potential in pancreatic cancer.MethodsTwo different mouse models of pancreatic cancer were used to assess the potential of this combination regimen. Therefore, effects on tumour growth kinetics and survival were charted. Differential effects on immune signatures was investigated using RNA sequencing. Functional immune subse..
View full abstract